What the FDA labels say about taking them together
Flibanserin and nirmatrelvir/ritonavir
Nirmatrelvir/ritonavir's FDA label of February 19, 2026 names flibanserin in its contraindications section; the flibanserin label PlainMeds reads does not name nirmatrelvir/ritonavir. The nirmatrelvir/ritonavir label: “Co-administration contraindicated due to potential for hypotension, syncope, and CNS depression.”
Check it at the source: the flibanserin FDA label on DailyMed (effective December 22, 2025, Sprout Pharmaceuticals, Inc.); the nirmatrelvir/ritonavir FDA label on DailyMed (effective February 19, 2026, Pfizer Laboratories Div Pfizer Inc).
What does the flibanserin label say about nirmatrelvir/ritonavir?
Flibanserin's label (effective December 22, 2025) does not name nirmatrelvir/ritonavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ADDYI), Sprout Pharmaceuticals, Inc., effective December 22, 2025 (SPL set 3819daf3-e935-2c53-c527-e1d57922f394), via openFDA; the full label on DailyMed
What does the nirmatrelvir/ritonavir label say about flibanserin?
Nirmatrelvir/ritonavir label, contraindicationsSerotonin receptor 1A agonist/serotonin receptor 2A antagonist: flibanserin
Nirmatrelvir/ritonavir label, drug interactionsDrug Class: Serotonin receptor 1A agonist/ serotonin receptor 2A antagonist; Drugs within Class: flibanserin; Effect on Concentration: ↑ flibanserin; Clinical Comments: Co-administration contraindicated due to potential for hypotension, syncope, and CNS depression [see ].
Source: FDA drug label (Paxlovid), Pfizer Laboratories Div Pfizer Inc, effective February 19, 2026 (SPL set 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Flibanserin | Nirmatrelvir/ritonavir | |
|---|---|---|
| Labeled for | n/a | COVID-19 |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $49.24 per unit 300-100 mg dose pack |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once